Evaluation of NRC Human Health Therapeutics: November 13, 2014

Download
  1. (PDF, 738 KB)
DOIResolve DOI: http://doi.org/10.4224/23001436
AuthorSearch for:
TypeCorporate Publication
Physical description52 p.
AbstractThis report presents the results of the 2013 14 evaluation of the National Research Council (NRC) Human Health Therapeutics (HHT) Portfolio. HHT mainly targets Canadian small and medium enterprises (SMEs) who develop therapeutics and vaccines to address unmet needs in human health. The Portfolio hosts three programs: Biologics and Subsequent Entry Biologics, Vaccines, and Therapeutics Beyond Brain Barriers (TBBB). The primary mode of interaction with these companies is the co-development of a product (therapeutic or vaccine) through R and D agreements. These co-development agreements are complemented by licensing and research services activities. Overall, these interactions are expected to de-risk the development of therapeutics and vaccines for HHT partners and accelerate the progress of candidates to clinical trials and market, thereby catalyzing the generation of wealth for industrial partners, increasing the availability of new or improved treatments and reducing health care costs.
Publication date
PublisherNational Research Council Canada. Office of Audit and Evaluation
Translation of
LanguageEnglish
AffiliationNational Research Council Canada; Audit and Evaluation
Peer reviewedNo
NPARC number23001436
Export citationExport as RIS
Report a correctionReport a correction
Record identifierb260e3b4-f4af-4000-99f7-40d920ea498c
Record created2017-02-07
Record modified2017-02-07
Bookmark and share
  • Share this page with Facebook (Opens in a new window)
  • Share this page with Twitter (Opens in a new window)
  • Share this page with Google+ (Opens in a new window)
  • Share this page with Delicious (Opens in a new window)